PROC and Sepsis: The recent market withdrawal of recombinant activated protein C (rhaPC), a natural anticoagulant used in the treatment of sepsis, represents the last chapter of a story characterized by serial failures of large-scale clinical trials designed to test the generally accepted assumption that coagulation activation and microvascular thrombosis were major determinants of tissue damage in sepsis [29].